Amgen (NASDAQ:AMGN) Research Coverage Started at Guggenheim
Guggenheim started coverage on shares of Amgen (NASDAQ:AMGN – Free Report) in a report released on Tuesday, Marketbeat.com reports. The firm issued a neutral rating and a $288.00 target price on the medical research company’s stock. A number of other research analysts have also commented on the company. UBS Group reissued a “neutral” rating and […]
Guggenheim started coverage on shares of Amgen (NASDAQ:AMGN – Free Report) in a report released on Tuesday, Marketbeat.com reports. The firm issued a neutral rating and a $288.00 target price on the medical research company’s stock. A number of other research analysts have also commented on the company. UBS Group reissued a “neutral” rating and […]
